Cefepime and all-cause mortality

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 640-641

  Paul, Mical ^a,b,c   Yahav, Dafna ^b,c   Fraser, Abigail ^d   Leibovici, Leonard ^b,c  

^a Unit of Infectious Diseases   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME;

ANTIBIOTIC THERAPY; CONFOUNDING VARIABLE; DATA ANALYSIS; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; SEPSIS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; HUMANS; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67651097462     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603587     Document Type: Letter

References (13)

1. Nguyen TD, Williams B, Trang E. Cefepime therapy and all-cause mortality. Clin Infect Dis 2009; 48:902-4.
2. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338-48.
3. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50:79-88.
4. Gomez L, Estrada C, Gomez I, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin in the treatment of patients with fever and granulocytopenia [abstract L-771]. In: Program and abstracts of the 41th Inter- science Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
5. Paul M, Yahav D, Fraser A, Sarid N, Leibovici L. The efficacy and safety of cefepime: systematic review and meta-analysis [abstract O- 156]. In: Program and abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (Nice, France). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2006.
6. Keirns CC, Carr BG. From the emergency department to vital statistics: cause of death uncertain. Acad Emerg Med 2008; 15:768-75.
7. Attems J, Arbes S, BohmG, Böhmer F, Lintner F. The clinical diagnostic accuracy rate regarding the immediate cause of death in a hospitalized geriatric population; an autopsy study of 1594 patients. Wien Med Wochenschr 2004; 154:159-62.
8. Ravakhah K. Death certificates are not reliable: revivification of the autopsy. South Med J 2006; 99:728-33.
9. Copelan E, Casper JT, Carter SL, et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007; 13:1469-76.
10. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43:447-59.
11. Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator associated pneumonia. Antimicrob Agents Chemother 2009; 53:1476-81.
12. Bhat SV, Peleg AY, Lodise TP Jr, et al. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gramnegative organisms. Antimicrob Agents Che- mother 2007; 51:4390-5.
13. Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic- pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006;58: 987-93.